Ventyx Biosciences develops oral small molecule drugs targeting the NLRP3 inflammasome to treat inflammatory disorders, with applications in cardiometabolic health, neurodegeneration, and autoimmunity
Ventyx Biosciences develops oral small molecule drugs targeting the NLRP3 inflammasome to treat inflammatory disorders, with applications in cardiometabolic health, neurodegeneration, and autoimmunity.